BV‐CHP is clearly the standard of care option for ALCL that show strong expression for CD30 whilst the benefit of this regimen in PTCL‐NOS and AITL subgroups that express CD30 not uniformly is uncertain. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.